newsfilter
← Latest News
Business Wire·

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Company to present three posters with data for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for idiopathic pulmonary fibrosis (IPF) New data from a phase 1 drug-drug interaction clinical study of cud